Marine sponge drug extends breast cancer survival: study

Jun 06, 2010

A new agent derived from a marine sponge can extend the survival rates of women with locally recurrent or metastatic breast cancer who already recieved extensive standard therapy, a new study unveiled Sunday found.

The synthetic component called eribulin mesylate mimics a component found naturally in sponges and can prevent cell devision, which causes cells to self-destruct, said study authors who presented their findings at the annual American Society of Clinical conference in Chicago.

In a randomized international trial, British researchers assessed the survival rates of 762 patients, treated either with eribulin or another therapy, almost always , and found the new therapy extended median overall survival by about 2.5 months.

"Until now, there hasn't been a standard treatment for women with such advanced . For those who have already received all of the recognized treatments, these are promising results," said lead study author Christopher Twelves.

"These findings may establish eribulin as a new, effective option for with heavily pre-treated metastatic breast cancer," said Twelves, head of the Clinical Cancer Research Groups at the Leeds Institute of Molecular Medicine in Britain.

Explore further: New breast cancer screening analysis confirms biennial interval optimal for average risk women

Related Stories

Study: Radiation boosts prostate cancer survival

Jun 06, 2010

(AP) -- Doctors are reporting a key advance in treating men with cancer that has started to spread beyond the prostate: survival is significantly better if radiation is added to standard hormone treatments.

Second lumpectomy for breast cancer reduces survival rates

Oct 02, 2008

A majority of women with breast cancer today are candidates for lumpectomy, allowing for conservation of most of their breast tissue. Results of a UC Davis study, however, show that a number of women whose cancer recurs in ...

Recommended for you

HLA expression tied to penile cancer outcomes

12 hours ago

(HealthDay)—Human leukocyte antigen (HLA) expression appears to be tied to clinical outcomes in penile cancer, according to a study published in the April issue of The Journal of Urology.

Study points to potential new lung cancer therapy

13 hours ago

New findings about regulation of PD-L1, a protein that allows cancer to evade the immune system, has shown therapeutic promise for several cancers, including the most common form of lung cancer.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.